Q-Line Biotech's total inventories for the quarter that ended in Mar. 2025 was ₹902 Mil. Q-Line Biotech's average total inventories from the quarter that ended in Mar. 2024 to the quarter that ended in Mar. 2025 was ₹977 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Q-Line Biotech's Net-Net Working Capital per share for the quarter that ended in Mar. 2025 was ₹-67.60.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Q-Line Biotech's Days Inventory for the
six
months ended in Mar. 2025 was 98.29.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Q-Line Biotech's Inventory Turnover for the quarter that ended in Mar. 2025 was 1.86.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Q-Line Biotech's Inventory-to-Revenue for the quarter that ended in Mar. 2025 was 0.31.
Q-Line Biotech (NSE:QLINE) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Q-Line Biotech's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Q-Line Biotech's Inventory to Revenue for the quarter that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Q-Line Biotech Total Inventories Related Terms
Q-Line Biotech Total Inventories Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Q-Line Biotech (NSE:QLINE) has a Total Inventories of ₹902 Mil as of Mar. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Q-Line Biotech and its competitors.
Is Q-Line Biotech's Total Inventories too high?
Q-Line Biotech's current Total Inventories is ₹902 Mil. Overall, Q-Line Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Total Inventories compare to ABT and SYK?
Q-Line Biotech's Total Inventories of ₹902 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Devices & Instruments company?
A good Total Inventories depends on the Medical Devices & Instruments industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Q-Line Biotech and its competitors. Q-Line Biotech's current Total Inventories is ₹902 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Total Inventories of ₹902 Mil. The current Total Inventories is ₹902 Mil. Q-Line Biotech's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Total Inventories is ₹902 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
12GF Score
Get the complete analysis for NSE:QLINE
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 